These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 20231400)

  • 41. Metformin and other biguanides in oncology: advancing the research agenda.
    Pollak M
    Cancer Prev Res (Phila); 2010 Sep; 3(9):1060-5. PubMed ID: 20810670
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Persistent interactions between biguanide-based compound NB325 and CXCR4 result in prolonged inhibition of human immunodeficiency virus type 1 infection.
    Thakkar N; Pirrone V; Passic S; Keogan S; Zhu W; Kholodovych V; Welsh W; Rando R; Labib M; Wigdahl B; Krebs FC
    Antimicrob Agents Chemother; 2010 May; 54(5):1965-72. PubMed ID: 20231400
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cervicovaginal safety of the formulated, biguanide-based human immunodeficiency virus type 1 (HIV-1) inhibitor NB325 in a murine model.
    Lozenski K; Kish-Catalone T; Pirrone V; Rando RF; Labib M; Wigdahl B; Krebs FC
    J Biomed Biotechnol; 2011; 2011():941061. PubMed ID: 22131821
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of human immunodeficiency virus type 1 infection on CCR5 and CXCR4 coreceptor expression on CD4 T lymphocyte subsets in infants and adolescents.
    Tuttle DL; Coberley CR; Xie X; Kou ZC; Sleasman JW; Goodenow MM
    AIDS Res Hum Retroviruses; 2004 Mar; 20(3):305-13. PubMed ID: 15117454
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein.
    Bosch B; Blanco J; Pauls E; Clotet-Codina I; Armand-Ugón M; Grigorov B; Muriaux D; Clotet B; Darlix JL; Esté JA
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4296-304. PubMed ID: 16189111
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Specific interactions between the viral coreceptor CXCR4 and the biguanide-based compound NB325 mediate inhibition of human immunodeficiency virus type 1 infection.
    Thakkar N; Pirrone V; Passic S; Zhu W; Kholodovych V; Welsh W; Rando RF; Labib ME; Wigdahl B; Krebs FC
    Antimicrob Agents Chemother; 2009 Feb; 53(2):631-8. PubMed ID: 19047650
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
    Fletcher P; Harman S; Azijn H; Armanasco N; Manlow P; Perumal D; de Bethune MP; Nuttall J; Romano J; Shattock R
    Antimicrob Agents Chemother; 2009 Feb; 53(2):487-95. PubMed ID: 19029331
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Polybiguanides, particularly polyethylene hexamethylene biguanide, have activity against human immunodeficiency virus type 1.
    Krebs FC; Miller SR; Ferguson ML; Labib M; Rando RF; Wigdahl B
    Biomed Pharmacother; 2005 Sep; 59(8):438-45. PubMed ID: 16154720
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells.
    Fletcher P; Kiselyeva Y; Wallace G; Romano J; Griffin G; Margolis L; Shattock R
    J Virol; 2005 Sep; 79(17):11179-86. PubMed ID: 16103169
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pre-incubation of cell-free HIV-1 group M isolates with non-nucleoside reverse transcriptase inhibitors blocks subsequent viral replication in co-cultures of dendritic cells and T cells.
    Njai HF; Lewi PJ; Janssen CG; Garcia S; Fransen K; Kestens L; Vanham G; Janssen PA
    Antivir Ther; 2005; 10(2):255-62. PubMed ID: 15865220
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors.
    Hartley O; Gaertner H; Wilken J; Thompson D; Fish R; Ramos A; Pastore C; Dufour B; Cerini F; Melotti A; Heveker N; Picard L; Alizon M; Mosier D; Kent S; Offord R
    Proc Natl Acad Sci U S A; 2004 Nov; 101(47):16460-5. PubMed ID: 15545608
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides.
    Van Herrewege Y; Vanham G; Michiels J; Fransen K; Kestens L; Andries K; Janssen P; Lewi P
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3684-9. PubMed ID: 15388420
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides.
    Catalone BJ; Kish-Catalone TM; Budgeon LR; Neely EB; Ferguson M; Krebs FC; Howett MK; Labib M; Rando R; Wigdahl B
    Antimicrob Agents Chemother; 2004 May; 48(5):1837-47. PubMed ID: 15105142
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides.
    Van Herrewege Y; Michiels J; Van Roey J; Fransen K; Kestens L; Balzarini J; Lewi P; Vanham G; Janssen P
    Antimicrob Agents Chemother; 2004 Jan; 48(1):337-9. PubMed ID: 14693562
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.